OBJECTIVE: Activation and dimerization of the ERBB family play a role in the pathogenesis and progression of ovarian cancer. We conducted a phase II trial to evaluate the activity and tolerability of lapatinib in patients with recurrent or persistent epithelial ovarian cancer (EOC) and to explore the clinical value of expression levels of epidermal growth factor receptors (EGFR), phosphorylated EGFR, HER-2/neu, and Ki-67, and the presence of EGFR mutations. METHODS: Eligible patients had recurrent or persistent EOC or primary peritoneal carcinoma, measurable disease, and up to 2 prior chemotherapy regimens for recurrent disease. Patients were treated with lapatinib 1500 mg/day. The primary endpoint of efficacy was 6-month progression free survival (PFS). RESULTS: Twenty-five of 28 patients were eligible and evaluable for analysis of efficacy and toxicity. Two (8.0%) were alive and progression-free at 6 months. No objective responses were observed. There were 1 grade 4 toxicity (fatigue) and few grade 3 toxicities. Associations between Ki-67 with prior platinum-free interval, PFS, and a polymorphism in EGFR were suggested. CONCLUSIONS: Lapatinib has minimal activity in recurrent ovarian cancer. Ki-67 expression may be associated with prior PFS and a polymorphism in EGFR exon 20 (2361G>A, Q787Q).
OBJECTIVE: Activation and dimerization of the ERBB family play a role in the pathogenesis and progression of ovarian cancer. We conducted a phase II trial to evaluate the activity and tolerability of lapatinib in patients with recurrent or persistent epithelial ovarian cancer (EOC) and to explore the clinical value of expression levels of epidermal growth factor receptors (EGFR), phosphorylated EGFR, HER-2/neu, and Ki-67, and the presence of EGFR mutations. METHODS: Eligible patients had recurrent or persistent EOC or primary peritoneal carcinoma, measurable disease, and up to 2 prior chemotherapy regimens for recurrent disease. Patients were treated with lapatinib 1500 mg/day. The primary endpoint of efficacy was 6-month progression free survival (PFS). RESULTS: Twenty-five of 28 patients were eligible and evaluable for analysis of efficacy and toxicity. Two (8.0%) were alive and progression-free at 6 months. No objective responses were observed. There were 1 grade 4 toxicity (fatigue) and few grade 3 toxicities. Associations between Ki-67 with prior platinum-free interval, PFS, and a polymorphism in EGFR were suggested. CONCLUSIONS:Lapatinib has minimal activity in recurrent ovarian cancer. Ki-67 expression may be associated with prior PFS and a polymorphism in EGFR exon 20 (2361G>A, Q787Q).
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Michael S Gordon; Daniela Matei; Carol Aghajanian; Ursula A Matulonis; Molly Brewer; Gini F Fleming; John D Hainsworth; Agustin A Garcia; Mark D Pegram; Russell J Schilder; David E Cohn; Lynda Roman; Mika K Derynck; Kimmie Ng; Benjamin Lyons; David E Allison; David A Eberhard; Thinh Q Pham; Randall C Dere; Beth Y Karlan Journal: J Clin Oncol Date: 2006-08-08 Impact factor: 44.544
Authors: A N Gordon; N Finkler; R P Edwards; A A Garcia; M Crozier; D H Irwin; E Barrett Journal: Int J Gynecol Cancer Date: 2005 Sep-Oct Impact factor: 3.437
Authors: D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich Journal: Science Date: 1989-05-12 Impact factor: 47.728
Authors: D W Rusnak; K Affleck; S G Cockerill; C Stubberfield; R Harris; M Page; K J Smith; S B Guntrip; M C Carter; R J Shaw; A Jowett; J Stables; P Topley; E R Wood; P S Brignola; S H Kadwell; B R Reep; R J Mullin; K J Alligood; B R Keith; R M Crosby; D M Murray; W B Knight; T M Gilmer; K Lackey Journal: Cancer Res Date: 2001-10-01 Impact factor: 12.701
Authors: Svetlana D Pack; Ozgül M Alper; Kurt Stromberg; Meena Augustus; Metin Ozdemirli; Anne M Miermont; Greg Klus; Marek Rusin; Rebecca Slack; Neville F Hacker; Thomas Ried; Zoltan Szallasi; Ozge Alper Journal: Cancer Res Date: 2004-02-01 Impact factor: 12.701
Authors: A Berchuck; A Kamel; R Whitaker; B Kerns; G Olt; R Kinney; J T Soper; R Dodge; D L Clarke-Pearson; P Marks Journal: Cancer Res Date: 1990-07-01 Impact factor: 12.701
Authors: J M Bartlett; S P Langdon; B J Simpson; M Stewart; D Katsaros; P Sismondi; S Love; W N Scott; A R Williams; A M Lessells; K G Macleod; J F Smyth; W R Miller Journal: Br J Cancer Date: 1996-02 Impact factor: 7.640
Authors: Kimberly K Leslie; Michael W Sill; Edgar Fischer; Kathleen M Darcy; Robert S Mannel; Krishnansu S Tewari; Parviz Hanjani; Jason A Wilken; Andre T Baron; Andrew K Godwin; Russell J Schilder; Meenakshi Singh; Nita J Maihle Journal: Gynecol Oncol Date: 2013-02-21 Impact factor: 5.482
Authors: Henry D Reyes; Kristina W Thiel; Matthew J Carlson; Xiangbing Meng; Shujie Yang; Jean-Marie Stephan; Kimberly K Leslie Journal: Mol Diagn Ther Date: 2014-04 Impact factor: 4.074
Authors: Hanqing Liu; Fang Xiao; Ilya G Serebriiskii; Shane W O'Brien; Marisa A Maglaty; Igor Astsaturov; Samuel Litwin; Lainie P Martin; David A Proia; Erica A Golemis; Denise C Connolly Journal: Clin Cancer Res Date: 2013-07-30 Impact factor: 12.531
Authors: Jason A Wilken; Tayf Badri; Sarah Cross; Rhoda Raji; Alessandro D Santin; Peter Schwartz; Adam J Branscum; Andre T Baron; Adam I Sakhitab; Nita J Maihle Journal: Future Med Chem Date: 2012-03 Impact factor: 3.808
Authors: William C Reinhold; Fathi Elloumi; Sudhir Varma; Jacques Robert; Gordon B Mills; Yves Pommier Journal: Transl Oncol Date: 2020-07-08 Impact factor: 4.243
Authors: Joseph J Caumanns; Katrien Berns; G Bea A Wisman; Rudolf S N Fehrmann; Tushar Tomar; Harry Klip; Gert J Meersma; E Marielle Hijmans; Annemiek M C Gennissen; Evelien W Duiker; Desiree Weening; Hiroaki Itamochi; Roelof J C Kluin; Anna K L Reyners; Michael J Birrer; Helga B Salvesen; Ignace Vergote; Els van Nieuwenhuysen; James Brenton; E Ioana Braicu; Jolanta Kupryjanczyk; Beata Spiewankiewicz; Lorenza Mittempergher; René Bernards; Ate G J van der Zee; Steven de Jong Journal: Clin Cancer Res Date: 2018-04-23 Impact factor: 12.531